The rhabdomyosarcoma market is projected to reach USD 1.74 Billion by 2030 at 3.80% CAGR during the forecast period 2023-2030.
The Rhabdomyosarcoma (RMS) market faces dynamic shifts in research, diagnosis, and treatment. With an increasing incidence in pediatric and young adult populations, pharmaceutical companies are intensifying efforts to develop targeted therapies. Current standard...
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
urdu